| Background:Endometrial cancer(endometrial carcinnoma) is a group of theepithelial malignant tumors occurring in the endometrium, it is also one of the threecommon malignant tumor of the female genital tract, accounting for about7%of thefemale systemic cancer,20to30%of the reproductive tract cancer. However,metastasis and invasion is the important feature of malignant tumors and also theleading cause of death of the cancer patients;after local recurrence or distantmetastasis of the endometrial cancer is an important factor impacting of the5-yearsurvival rate. Currently, approximately80%of patients with endometrial cancer hadbeen diagnosed in Phase I and with good clinical results after active treatment,however, there is still a large proportion of patients with recurrence and distantmetastasis probbly for the reason that the already proliferation of tumor cells is notdetected resulting in the clinical metastasis; then the positive detection of theproliferation of tumor cells in the peripheral blood may be used as selection criteria.CK20is a newly discovered tissue-specific markers that first discovered by Mollequal in the1890s.CK20synthes firstly appeared in the mucosal epithelia in embryosin the first eight weeks, it has more stringent epithelial tissue specificity.CK20is inhigh expression in gastrointestinal epithelium, transitional cell, Merkell cells,mucinous ovarian cancer,and also has a differ-ent level of expression in endometrialcancer, gallbladder and pancreas.however the expression of CK20is not observed innon-epithelial tissue and cells (such as blood, bone marrow, lymph nodes, etc.).Thereby CK20can be used as markers for detecting some tumors of epithelial origin.Thus CK20also becomes a hot research topic in the field of cancer molecular biology.This experiment uses the fluorescence quantitative PCR (FQ-PCR) to observethe expression of CK20gene product in the peripheral blood of patients withendometrial cancer,then analysis of the relationship between the peripheral blood ofCK20gene product expression in endometrial cancer clinical pathologicalparameters,as well as investigates using fluorescent quantitative PCR CK20to predictendometrial cancer micrometastases as well as to determine the prognostic value.Objective: To detect the mRNA expression of CK20gene in peripheral bloodcells of endometrial carcinoma patients by using of real-time quantitative PCR, and to explore its diagnostic value of the expression in peripheral blood cells ofendometrial cancer micrometastasis..Method:44endometrial carcinoma patients,34uterine benign diseases patientsand32healthy volunteers of CK20mRNA in peripheral blood cells were detected byfluorescent quantitative PCR. Analysis of the relationship between its expression witheach pathological parameters of endometrial carcinoma patients.Results: The levels of44endometrial carcinoma patients CK20mRNA inperipheral blood are detected positive in12patients, the positive rate is33.3%;Among the uterine benign diseases patients and peripheral blood of healthy women,there is no its expression detected，The difference was statistically significant（χ~2=20.204，P＜0.05）. The expression level of CK20mRNA has statisticallysignificant relationship with clinical stage（χ~2=16.712，P＜0.05）, lymph nodemetastasis（χ~2=6.381，P＜0.05） and depth of invasion（χ~2=6.381，P＜0.05）; buthas nothing to do with pathological grade（χ~2=0.229，P＜0.05） or whethermenopause （χ~2=0.004，P＞0.05）.Conclusions: Fluorescence quantitative PCR can detect the expression of CK20mRNA in the peripheral blood cells of patients with endometrial carcinoma rapidlyand sensitively, which will contribute to the early detection of endometrial cancermicrometastasis, and has an extremely important signifycance in comprehensivetreatment in a timely manner, predictting prognosis, efficacy monitoring andimproving the survival rate of patients. |
PDF Full Text Request